United States Patent 6,979,437: Scope, Claim Architecture, and Patent Landscape

US 6,979,437 claims a narrow but high-leverage device-pharma linkage: delivering drugs for central nervous system (CNS) disorders via pulmonary administration of dry powder particles that have low tap density (<0.4 g/cm³) and enable systemic exposure at doses at least 2x lower than oral, including rescue therapy use cases. Claim scope is built around four pillars: (1) route (respiratory tract delivery to CNS), (2) dose reduction metric versus oral (>=2x less), (3) powder rheology/packing property (tap density <0.4 g/cm³), and (4) particle design windows (aerodynamic/size metrics; optional excipients like phospholipids and amino acids).

Because the claim set is method-centric and composition-agnostic beyond powders/excipients, the enforceable zone sits where competitors combine inhaled dry powder CNS drugs with low tap density powder engineering and dose-reduction demonstrations tied to oral comparators.

What does claim scope cover in plain terms?

Core independent claim features (claim 1)

Claim 1 is the structural center of gravity. It covers:

Method for treating CNS disorder
Administering to the respiratory tract of a patient
Drug treats the CNS disorder
Pulmonary delivery (delivery to pulmonary system)
Dose reduction versus oral: dose is at least about 2 times less than that required by oral administration
Dry powder particle parameter: drug is present in dry powder particles having tap density < 0.4 g/cm³

This creates a three-part infringement test:

Is the therapy a CNS disorder method?
Is delivery pulmonary using dry powder particles with tap density < 0.4 g/cm³?
Is the administered dose at least 2x lower than oral to achieve therapeutic effect?

Dependent claim boundaries that narrow the zone

The dependent claims tighten the scope into predictable “design-around risk” pockets:

Dose reduction bands (claims 2-3, 18)
- Claim 2: dose is 2x to 5x less than oral
- Claim 3: dose is 2x to 10x less than oral
- Claim 18 adds: “at least 2x less than routes other than IV” as comparator set
Anatomical deposition (claims 4, 28)
- Alveoli region delivery is required in claims 4 and 28
Therapy timing (claims 5-6)
- Rescue therapy
- Ongoing treatment
Disease list inclusion (claim 7)
- Explicit disorder group includes: anxiety, psychosis, depression, bipolar disorder, OCD, convulsions/seizures/epilepsy, Alzheimer’s, ADHD, migraines
Drug loading thresholds in powder (claims 8-10)
- =20 wt% (claim 8)
- =40 wt% (claim 9)
- =50 wt% (claim 10)
Particle size/aerodynamic windows (claims 11-13)
- MMAD < 5 microns (claim 11)
- MD geometric > 5 microns (claim 12)
- MMAD < 3 microns (claim 13)
Excipients/external structure components (claims 14-16)
- Particles include phospholipid (claim 14)
- Particles include amino acid (claim 15)
- Amino acid is leucine (claim 16)
Delivery device type (claim 17)
- Dry powder inhaler

What do the additional independent claims broaden or lock down?

Claim 19: ketoprofen-specific CNS delivery

Claim 19 is a dedicated ketoprofen route-to-CNS method:

Pulmonary dry powder
Tap density <0.4 g/cm³
Dose >=2x less than oral
Administer to respiratory tract for CNS delivery
Includes “patient in need of treatment or rescue therapy with ketoprofen”

This is typically the most commercially actionable element when a specific CNS drug has an inhaled dry powder candidate.

Claim 20: benzodiazepine-specific rescue/intended delivery

Claim 20:

Pulmonary rescue therapy
Dry powder tap density <0.4 g/cm³
Dose >=2x less than oral
Applies to “benzodiazepine drug”

Claim 21: “providing rescue therapy” composition-defined powder

Claim 21 is a rescue therapy method defined by particles:

Administer particles comprising an effective amount of a benzodiazepine drug
Tap density <0.4 g/cm³
Pulmonary system delivery by definition It removes some comparator details (it does not re-state dose reduction vs oral in the text you provided), making it potentially broader in proving infringement if tap density and effective amount criteria are met.

Claim 22: panic attack within rescue therapy

Claim 22 narrows the benzodiazepine rescue therapy to panic attacks.

Claims 23-28: explicit particle design window for benzodiazepine powders

Claims 23-28 add quantification that is often used to police powder engineering:

Drug content: 1 to 90 wt% (claim 23)
Volume median geometric diameter: 5 to 30 microns (claim 24)
Aerodynamic diameter: 1 to 5 microns (claim 25)
Sub-band splits:
- 1 to 3 microns (claim 26)
- 3 to 5 microns (claim 27)
Alveoli delivery: claim 28

This matters because powder developers commonly target aerodynamic size while changing excipient architecture. Here, the patent ties enforceability to a specific tap density and specific size windows.

How does excipient language affect landscape and design-around?

Phospholipid and thermal behavior (claims 14, 29-31)

Particles include phospholipid (claim 14; claim 29)
Phospholipid matrix transition temperature: no higher than patient physiological temperature (claim 30)
Phospholipid present at 10 to 99 wt% (claim 31)

This combination is a higher-barrier technical constraint for competitors who would otherwise “swap” phospholipids to adjust performance while maintaining tap density and aerodynamic size.

Amino acids and hydrophobic amino acids (claims 15-16, 32-33)

Particles include amino acid (claim 15); leucine specifically in claim 16
Hydrophobic amino acid (claim 32)
Hydrophobic amino acid at least 10 wt% (claim 33)

Calcium chloride (claim 34)

Particles further include calcium chloride

Delivery device mechanics (claims 35-36)

Dry powder inhaler (claim 35)
Metered dose inhaler (claim 36)

These device claims matter for product format competitors: if the product uses a metered dose inhaler with dry powder particles that meet tap density criteria, it can remain within reach.

What is the practical infringement map?

The “must-have” technical features

Across independent claim 1 plus benzodiazepine/tighter claims, enforceable product attributes center on:

Route: pulmonary delivery via respiratory tract administration
Particle form: dry powder particles
Powder packing: tap density < 0.4 g/cm³
Dose reduction: at least 2x less than oral (explicitly in claims 1-3, 18-20, 19; rescue-focused claim 21 as provided does not restate it)
Targeting CNS therapy: method for CNS disorders; benzodiazepine subset explicitly for rescue therapy

The “often decisive” optional constraints

If the competitor matches the independent claim, dependent claims can still provide stronger footholds if the competitor’s formulation also meets:

Alveoli delivery
MMAD windows (<5 µm or <3 µm)
Drug load (>=20/40/50 wt%)
Phospholipid inclusion and transition temperature criterion
Amino acid class (hydrophobic amino acid; leucine as specific example)
Calcium chloride
Specified aerodynamic size ranges (1-5 µm; or 1-3 and 3-5)

What is the claim strategy and likely validity posture?

1) Claim 1 is the general platform

Claim 1 is broadest in therapeutic framing and excipient generality, while it still locks to:

dose reduction versus oral
pulmonary delivery
tap density <0.4 g/cm³

That combination often gives examiners a clearer technical distinction versus “any inhaled CNS drug.”

2) Ketoprofen and benzodiazepines are carve-outs

Claim 19 and claim 20 isolate commercially relevant molecules:

Ketoprofen
Benzodiazepines (rescue)

This indicates the application aimed at both platform coverage and molecule-specific coverage.

3) Rescue therapy versions focus on urgent use

Claim 21-22 and the benzodiazepine family create a narrower clinical intent:

rescue therapy
panic attack as a specific use

This can drive narrower prosecution history but can also help enforcement because competitors may market for “acute” outcomes.

Patent landscape implications (business-level)

Without the full prosecution history, family members, and cited prior art from the publication record, the landscape analysis below focuses on the claim-driven competitive risk zone created by the claim parameters you provided.

Where competitors face risk

A competitor developing an inhaled dry powder CNS drug faces high infringement risk if the product matches all of the following:

Tap density <0.4 g/cm³ (primary claim anchor)
Pulmonary delivery
Demonstrated dose that is at least 2x less than oral (for the claims that require oral comparator)
Particle size in the sub-5 µm aerodynamic regime (often needed for alveolar deposition and frequently used in product development)
For benzodiazepine rescue products: inclusion of benzodiazepine and dry powder design that aligns with size/load windows

Where design-around is possible (but technical)

Competitors can attempt to avoid by changing one or more claim anchors:

Tap density: using powders with tap density at or above 0.4 g/cm³
Dose comparison design: avoid the “2x less than oral” relationship in the labeled dose-efficacy regime (this is hard because clinical efficacy can effectively force dosing equivalence)
Particle engineering: moving aerodynamic diameter outside 1-5 µm or MMAD out of <5 µm/<3 µm bands (also hard because deposition targets often require small sizes)
Excipients: omit phospholipids or amino acids, or select phospholipids with transition temperature above physiological temperature (only directly relevant to dependent claims; however they can still drive clearer enforcement positions)

Device choice is not a free pass

Because claim 36 includes metered dose inhaler, device selection alone may not avoid liability if the formulation still uses the claimed dry powder parameter set.

Claim-by-claim scope matrix (what each claim adds beyond claim 1)

Claim	Additional limiting element(s) vs claim 1 (as provided)	Scope impact
2	Dose: 2x to 5x less than oral	narrows to mid-range dose reduction
3	Dose: 2x to 10x less than oral	narrows to broader reduction band
4	Delivery to alveoli region	deposition-specific narrowing
5	Rescue therapy	clinical timing narrowing
6	Ongoing treatment	timing narrowing
7	Listed CNS diseases	narrows disease applicability to listed group
8	Drug loading >=20 wt%	composition quantitative narrowing
9	Drug loading >=40 wt%	composition quantitative narrowing
10	Drug loading >=50 wt%	composition quantitative narrowing
11	MMAD <5 µm	aerosol deposition narrowing
12	MD geometric >5 µm	particle geometry constraint
13	MMAD <3 µm	more stringent aerosol constraint
14	Phospholipid included	excipient inclusion narrowing
15	Amino acid included	excipient inclusion narrowing
16	Amino acid is leucine	specific excipient narrowing
17	Dry powder inhaler	device form narrowing
18	Dose reduction comparator: “other than IV”	changes comparator set; still >=2x less
19	Ketoprofen-specific method	molecule-specific coverage
20	Benzodiazepine-specific method	molecule/class coverage
21	Rescue therapy benzodiazepine particles; tap density <0.4	rescue-focused particle method; comparator dose not stated in your text
22	Rescue therapy for panic attack	indication narrowing
23	Benzodiazepine content 1-90 wt%	loading window
24	Volume median geometric diameter 5-30 µm	geometric window
25	Aerodynamic diameter 1-5 µm	deposition window
26	Aerodynamic diameter 1-3 µm	deposition sub-window
27	Aerodynamic diameter 3-5 µm	deposition sub-window
28	Delivery to alveoli	deposition narrowing
29	Phospholipid included (benzodiazepine set)	excipient narrowing
30	Phospholipid transition temperature <= physiological	functional excipient property narrowing
31	Phospholipid amount 10-99 wt%	excipient loading window
32	Hydrophobic amino acid included	excipient class narrowing
33	Hydrophobic amino acid at least 10 wt%	excipient loading narrowing
34	Calcium chloride included	excipient addition
35	Dry powder inhaler (benzodiazepine set)	device narrowing
36	Metered dose inhaler (benzodiazepine set)	device narrowing

Key Takeaways

US 6,979,437 is a pulmonary dry powder CNS delivery platform patent anchored by tap density <0.4 g/cm³ and dose at least 2x less than oral (where explicitly claimed).
The claim set provides enforceable hooks at the formulation physics level (tap density + aerodynamic size) and at the clinical positioning level (CNS disorders, rescue therapy, panic attacks).
Ketoprofen and benzodiazepines are explicitly claimed, indicating targeted molecule coverage layered onto a broader inhalation/powder platform.
Dependent claims add multiple technical constraints (alveoli targeting, MMAD thresholds, drug loading, phospholipids and phospholipid transition temperature, hydrophobic amino acids like leucine, calcium chloride), which increases the number of potential infringement “combinations” for products that match the full formulation profile.

FAQs

1) Does the patent require a specific dry powder inhaler device?

No for claim 1 (it says administering to the respiratory tract with pulmonary delivery), but claim 17 narrows to dry powder inhaler, and claims 35-36 cover both dry powder inhaler and metered dose inhaler for the benzodiazepine rescue set.

2) What parameter most directly controls whether a formulation falls within scope?

The tap density <0.4 g/cm³ requirement is the repeated formulation anchor across the main independent and benzodiazepine claims.

3) Is the “2x less than oral” dose metric mandatory for every claim?

It is explicit in claims 1-3, 18, 19, and 20 as provided. For the benzodiazepine rescue particle method in claim 21 as provided, the text does not restate the oral comparator in the portion you provided.

4) Are particle size ranges central to the independent claim?

Particle size ranges (MMAD <5 µm, MMAD <3 µm, aerodynamic ranges) appear in dependent claims (11-13 and 24-27). Claim 1 focuses on tap density, pulmonary delivery, and dose reduction vs oral.

5) Which drug areas are most clearly covered?

CNS disorders generally under claim 1, with explicit molecule/class claims for ketoprofen (claim 19) and benzodiazepines (claims 20-21 and dependent panic attack and particle property claims).

References (APA)

[1] United States Patent 6,979,437. (n.d.). Claims as provided by user.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2001291122	⤷ Start Trial
Australia	9112201	⤷ Start Trial
Canada	2421974	⤷ Start Trial
Cyprus	1118851	⤷ Start Trial
Denmark	1318785	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,979,437

Summary for Patent: 6,979,437